Inhibition of C5 or absence of C6 protects from sepsis mortality
- 14 December 2004
- journal article
- Published by Elsevier BV in Immunobiology
- Vol. 209 (8), 629-635
- https://doi.org/10.1016/j.imbio.2004.09.004
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- The Pathophysiology and Treatment of SepsisThe New England Journal of Medicine, 2003
- Protective effects of anti‐C5a peptide antibodies in experimental sepsisThe FASEB Journal, 2001
- Predominant role for C5b-9 in renal ischemia/reperfusion injuryJCI Insight, 2000
- ELUCIDATION OF THE EARLY EVENTS CONTRIBUTING TO ZYMOSAN-INDUCED MULTIPLE ORGAN DYSFUNCTION SYNDROME USING MIP-1α, C3 KNOCKOUT, AND C5-DEFICIENT MICEShock, 1999
- Mechanisms of Enhanced Lung Injury during SepsisThe American Journal of Pathology, 1999
- C5b-7 and C5b-8 precursors of the membrane attack complex (C5b-9) are effective killers of E. Coli J5 during serum incubationImmunological Investigations, 1997
- Inhibition of interleukin‐6 synthesis in an animal model of septic shock by anti‐C5a monoclonal antibodiesEuropean Journal of Immunology, 1996
- Deficiency of complement factor C5 reduces early mortality but does not prevent organ damage in an animal model of multiple organ dysfunction syndromeCritical Care Medicine, 1995
- The Role of C5 in Septic Lung InjuryAnnals of Surgery, 1985
- Complement Deficiency States and InfectionMedicine, 1984